And you could argue that these previous development efforts, although they were subsequently abandoned, prepared INO to respond quickly with a COVID vaccine candidate. This is all part of the dues that must be paid to develop an efficient vaccine platform. And, with this advanced platform, they should be able to lower the expense/effort to bring new vaccines to market.
This may be particularly useful for future pandemics because I don't think COVID-19 will be the last pandemic we'll have to deal with in our lifetimes.
Market Data 
Markets 
AI
